Get started
Author

Helen Weston

Observed names: H. Weston, Weston Helen
OpenAlex ID: A5079905005
Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population
2010 · Kirk Morris, Helen Weston, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 28
Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy
2016 · Tanja M. Windegger, Christine A. Lambooy, et al. · Transfusion Medicine Reviews · 25
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
2024 · Peter Mollee, John Reynolds, et al. · Blood Advances · 19
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
2024 · Zoe K. McQuilten, Robert Weinkove, et al. · Blood Advances · 15
Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
2021 · Tanja M Windegger, Janine English, et al. · Asia-Pacific Journal of Clinical Oncology · 12
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
2024 · Sara Carrillo de Albornoz, Alisa M. Higgins, et al. · Blood Advances · 11
PDF
Bortezomib use and outcomes for the treatment of multiple myeloma
2020 · Crystal Loke, Peter Mollee, et al. · Internal Medicine Journal · 8
A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)
2020 · Peter Mollee, John Reynolds, et al. · Blood · 5
Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)
2024 · Sueh-Li Lim, John Reynolds, et al. · Blood · 4
Hypereosinophilic syndrome with cutaneous manifestations successfully treated with Dupilumab as a sole agent: A case report
2023 · Kayla Scully, Emily Shao, et al. · Australasian Journal of Dermatology · 4
PDF
A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)
2021 · Peter Mollee, John Reynolds, et al. · Blood · 3
Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN
2022 · Liesl Butler, Christine Lee, et al. · Blood · 1
Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia
2010 · H. Weston, V. Cowell, et al. · Internal Medicine Journal · 1
PA-424 Risk-Directed Front-Line Therapy for Newly Diagnosed Multiple Myeloma (NDMM) incorporating selinexor - The RIDDLE-MX Trial AMaRC 21-04
2026 · Sueh-li A. Lim, Yu Jin Kim, et al. · Clinical Lymphoma Myeloma & Leukemia
Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)
2025 · Sueh-Li Lim, John Reynolds, et al. · Blood
PD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial
2024 · Sara Carrillo De Albornoz, Alisa Higgins, et al. · International Journal of Technology Assessment in Health Care
PDF
Subcutaneous immunoglobulin in patients with common variable immunodeficiency
2018 · Tanja Windegger, Karen Morwood, et al. · Internal Medicine Journal
JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocytosis (ET).
2007 · Helen Weston, Robert Bird, et al. · Blood
Works count: 18
Citation count: 136
H-index: 7
I10-index: 6
Year
Topic
Type